KEYNOTE-059, trial summary

A randomised clinical trial investigating the effect of pembrolizumab versus nil in

        Z

NCT02335411    JAMA Oncol 2018;4:e180013  



Studied treatment
Control treatment



Patients
Group sizes-9 / -9



Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design Single-arm study



EndpointX1N1X0N0TE95% CI ORR - -9 - -9 no data OS - -9 - -9 no data PFS - -9 - -9 no data0,22,01,0

Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Ros Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol 2018;4:e180013     [PMID: 29543932]   link to pdf   add to Mendeley  

Links

ASCO post

ClinicalTrial.gov record NCT02335411



Registering number NCT02335411 (see trial on clinicaltrials.gov)
Code Name